Last reviewed · How we verify
Cx611
At a glance
| Generic name | Cx611 |
|---|---|
| Sponsor | Tigenix S.A.U. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cx611-0204 SEPCELL Study (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cx611 CI brief — competitive landscape report
- Cx611 updates RSS · CI watch RSS
- Tigenix S.A.U. portfolio CI